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The telomerase reverse transcriptase is limiting and necessary
for telomerase function in vivo
Y. Liu*, B.E. Snow*, M.P. Hande†, D. Yeung*‡, N.J. Erdmann*, A. Wakeham*,
A. Itie*, D.P. Siderovski§, P.M. Lansdorp¶, M.O. Robinson‡ and L. Harrington*
Mammalian telomerase is essential for the
maintenance of telomere length [1–5]. Its catalytic core
comprises a reverse transcriptase component (TERT)
and an RNA component. While the biochemical role of
mammalian TERT is well established [6–11], it is
unknown whether it is sufficient for telomere-length
maintenance, chromosome stability or other cellular
processes. Cells from mice in which the mTert gene had
been disrupted showed progressive loss of telomere
DNA, a phenotype similar to cells in which the gene
encoding the telomerase RNA component (mTR) has
been disrupted [1,12]. On prolonged growth, mTert-
deficient embryonic stem (ES) cells exhibited genomic
instability, aneuploidy and telomeric fusions. ES cells
heterozygous for the mTert disruption also showed
telomere attrition, a phenotype that differs from
heterozygous mTR cells [12]. Thus, telomere
maintenance in mammals is carried out by a single,
limiting TERT.
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Results and discussion
We disrupted the telomerase-specific motif and the first
three of the seven reverse transcriptase motifs of mTert by
gene targeting (Figure S1a in the Supplementary material).
ES cell clones and mice disrupted for one (mTert+/–) or both
(mTert–/–) alleles of mTert were confirmed by PCR and
Southern blot analysis (Figure S1b in the Supplementary
material, and data not shown). The mTert–/– ES cell clones
and G1 mouse tissues did not possess any detectable mTert
transcript (Figure 1a and data not shown), which differs
from the mTert knockout mice produced by Yuan et al. [13].
The latter knockout mice produce a shorter mTert tran-
script missing the targeted exons. The mTert-deficient mice
generated by us were viable for at least four generations.
To determine the requirement of mTERT for telomerase
catalysis in vivo, the telomere repeat amplification proto-
col (TRAP) [14] was performed on four independently
derived mTert–/– ES cell clones and several mouse tissues.
No telomerase activity was detected in all mTert–/–
ES cell clones, but both the mTert+/– and mTert+/+ ES cell
clones possessed telomerase activity (Figure 1b upper
panel and data not shown). Using semi-quantitative mea-
surements in which twofold changes in telomerase activ-
ity would be detectable, there was no difference in
telomerase activity between mTert+/+ and mTert+/– ES cell
lysates (Figure 1b, lower panel). Telomerase activity was
restored by transfection of mTert into mTert–/– ES cells
(Figure 2 in the Supplementary material). In tissue
extracts from testes, liver, thymus, lung and kidney
of mTert+/+ and mTert+/– mice, telomerase activity was
readily detected, but in mTert–/– mice telomerase activity
was undetectable (Figure S2 in the Supplementary mate-
rial and data not shown). Similar results were obtained
when telomerase activity was measured using the conven-
tional telomerase elongation assay, which does not rely on
PCR amplification [15,16] (data not shown).
Mice and ES cells disrupted for the telomerase RNA
component undergo telomere shortening and eventually
show an increase in end-to-end chromosome fusions
[1,3,4,12]. To examine the consequences of mTert defi-
ciency on telomere-length maintenance, we analyzed
telomere lengths in four cultured mTert–/– ES cell clones
upon prolonged culture. As mTert+/– and mTert–/– clones
have undergone more population doublings during G418
selection than the parental line, the early passages
(referred to as P1) from each genotype were not strictly
equivalent (Figure 2a). Using fluorescence in situ hybridiza-
tion (FISH) combined with flow cytometry (Flow–FISH)
[17], we observed that all four mTert-deficient ES cell
clones progressively lost telomeric DNA with increasing
passage in culture (Figures 2a and 3b). In contrast, wild-
type ES cells did not show any significant alteration in
telomere fluorescence, regardless of the total number of
population doublings (Figures 2a and 3b). Interestingly,
in later passages of mTert+/– ES cells, we also observed a
loss of telomeric DNA with successive growth in culture
(Figures 2a and 3b). Similar results were also obtained
with another mTert+/– ES cell line (data not shown).
Therefore, removal of one allele of mTert was sufficient to
confer a telomere-shortening phenotype in ES cells.
G1 mTert–/– and mTert+/– mice possessed a similar telom-
ere signal intensity as wild-type G1 littermates (Figure 2b).
However, G2 mTert-deficient mice showed a significant
reduction in relative telomere length compared with
wild-type and G1 mTert-deficient mice (Figure 2b). The
telomeric restriction fragments (TRFs) in mTert+/–,
mTert–/– and wild-type ES cells from early (P1) and later
passages (P25 and 50) were also monitored by pulsed-
field gel electrophoresis. Although differences in telom-
ere length are typically less evident by this method [1],
nonetheless a modest reduction in TRF length was
observed in the late passages of mTert+/– and mTert–/–
ES cells, but not in the wild-type ES cells (Figure S3 in
the Supplementary material).
To examine chromosome stability in late passage mTert+/–
and mTert–/– ES cells, we performed FISH analysis on
metaphase spreads (Figure 3). All passages of wild-type
ES cells and early passages of mTert+/– and mTert–/– ES
cells showed no overall changes in telomere signal inten-
sity. However, late passages of mTert+/– and mTert–/– ES
cells possessed decreased telomere signal intensity at some
chromosome ends (Figure 3). Aneuploidy was elevated in
late passages of mTert+/– and mTert–/– ES cells compared
with wild-type ES cells. However, only in mTert–/– ES cells
at P50 (~300 population doublings) was a significant
increase in end-to-end chromosome fusions observed
(Figure 3, Table 1). Although later passages of mTert+/– ES
cells possessed shortened telomeres, no end-to-end fusions
were evident. Mitogen-stimulated cells from spleen of G1
and G2 mTert–/– mice also did not exhibit any increase in
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Figure 1
Disruption of the mTert gene in ES cells and
mice. (a) Detection of mTert transcript by
reverse transcription (RT)–PCR in G1 mice
(testis) and ES cells. The upper panel shows
the mTert cDNA product encompassing the
targeted exons in each respective genetic
background. The same results were also
obtained from the PCR primer sets derived
from the 5′ and 3′ regions of the mTert cDNA
(data not shown). A control β-actin RT–PCR
product is shown in the bottom panel.
(b) Telomerase activity in mTert-deficient
ES cells and tissues. Upper panel, TRAP was
performed for 20 PCR cycles on cell extracts
(1.0, 0.5, 0.25 and 0.125 µg) prepared from
wild-type, mTert+/–, and mTert–/– ES cell
extracts, and on 10, 5 and 2.5 µl of partially
purified human Raji cell lysate. Arrow, internal
PCR standard; asterisk, a non-specific
product from mouse extracts that is resistant
to RNase A treatment. Lower panel, the
telomerase extension products were
normalized to the internal standard using NIH
Image Quant analysis. In each sample, data
were pooled from three individual experiments
(error bars represent the SD). 
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Figure 2
Analysis of telomere length in ES cells, splenocytes and thymocytes
by Flow–FISH. (a) Average telomere fluorescence in early and late
passages of wild-type, mTert+/–, and four mTert–/– ES cell clones.
The MESF (molecules of equivalent soluble fluorochrome) value
represents one individual ES clone at the indicated passage; thus,
there are no error bars. (b) The average telomere fluorescence in
splenocytes and thymocytes derived from G1 and G2 mTert–/– mice.
In each set, data were pooled from at least five individual mice (error
bars represent the SD).
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chromosomal aberrations compared with wild-type mice
(Table 1, and data not shown). This phenotype is similar to
mTR-deficient mice, in that the appearance of end-to-end
fusions occurs only in later generations [1,3,4,12].
The first genetic evidence to establish the importance of
TERT in telomere-length maintenance was obtained in
the yeasts Saccharomyces cerevisiae [18,19] and Schizosaccha-
romyces pombe [20]. Recent evidence for a single TERT in
multicellular organisms has been demonstrated in Ara-
bidopsis thaliana [21]. We have shown that murine TERT,
like the telomerase RNA, is not immediately essential for
normal development and cell viability but is required for
telomere-length maintenance in vivo [1,12]. While telom-
ere length and chromosome stability was not analyzed in
the previously reported mTert–/– mice, the presence of 3′
telomere single-stranded DNA (‘G-strand tails’) was pre-
served [13]. It remains to be determined whether late
generations of mTert–/– mice (G4 or later) show a similar
phenotype as mTR-deficient mice, such as end-to-end
chromosome fusions, apoptosis, and defects in cellular
proliferation. Telomere shortening rates between ES cells
and mice would be difficult to equate, and it will be nec-
essary to compare the telomere shortening phenotypes of
mTR- and mTert-deficient mice in the same genetic back-
ground. In S. cerevisiae, deletion of the telomerase RNA
component (TLC1) and the TERT EST2 are phenotypi-
cally indistinguishable [18,19,22].
Interestingly, ES cells deficient in one allele of mTert lost
telomeric DNA in successive passages. These results con-
trast with mTR+/– ES cells, in which the average TRF
length was virtually unchanged on prolonged culture [12].
These results suggest that TERT is a limiting component
for telomere-length maintenance, at least in this strain of
ES cells. However, we were unable to detect a repro-
ducible difference in telomerase activity in vitro between
wild-type and heterozygous ES cells or testis. These
results differ from the mTert+/– mice generated by Yuan
et al. in which telomerase activity was decreased in het-
erozygous animals (as measured by the stretch-PCR telom-
erase assay) [13]. In our studies, despite the obvious loss of
telomere DNA in vivo, assiduous efforts to detect even a
twofold difference in telomerase activity were unsuccessful
(Figure 1b, data not shown). This discrepancy could be the
result of different genetic backgrounds or differences in
telomerase extension conditions in vitro. It is also possible
that a truncated mTERT protein, if present in the mTert+/–
mice generated by Yuan et al., could decrease telomerase
activity through a ‘dominant-negative’ mechanism. Arabi-
dopsis tissues heterozygous for AtTERT also showed no
detectable difference in telomerase activity, but telomere
length in successive generations of AtTERT+/– tissues was
not examined [21]. There may therefore be limitations to
the in vitro telomerase assay in assessing subtle differences
in the dosage of telomerase components in vivo.
It will be important to determine whether the mTert hap-
loinsufficiency can be extended to other murine genetic
backgrounds and other organisms. Haploinsufficiency of
individual telomerase components has not been noted
previously, but in S. cerevisiae multiple heterozygous com-
binations of different telomerase components do appear to
exhibit telomere shortening [19,23]. It was suggested that
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Figure 3
FISH analysis from early (P1) or late passage
(P50) ES cells. (a) Representative metaphase
preparations of P1 or P50 wild-type, mTert+/–
and mTert–/– ES cells. Note the reduced
telomeric signal on some chromosome ends
in late passage mTert+/– and mTert–/– ES
cells (arrows), and an overall heterogeneity in
the telomere fluorescence, which is also
observed in mice and ES cells lacking the
telomerase RNA component [1,12]. End-to-
end fusions were visible in mTert–/– ES cells
at P50 (asterisk). Metaphase spreads, FISH
and image analyses were performed as
described previously [1,27]. The Cy-3-labeled
(CCCTAA)3 PNA was used as a probe.
(b) Histogram of Flow-FISH analysis of early
and late passage ES cells. The data is
shown for the same clones as in (a). The
horizontal axis represents the relative
telomere fluorescence intensity of individual
cells, and the vertical axis shows the
distribution of signal intensity in the
population (see Supplementary material for
methodological detail).     Current Biology
Relative telomere
fluorescence intensity
E
ve
nt
s P1
P50(b)(a)
mTert–/–
P1
mTert–/–
P50 *
mTert+/–
P50
Wild type
P50
mTert+/–
P1
Wild type
P1
50
40
30
20
10
0
0 200 400 600 800 1000
Relative telomere
fluorescence intensity
E
ve
nt
s 5040
30
20
10
0
0 200 400 600 800 1000
Relative telomere
fluorescence intensity
E
ve
nt
s 5040
30
20
10
0
0 200 400 600 800 1000
Wild type
mTert+/–
mTert–/–
‘additive haploinsufficiency’ could result from perturbations
in the stoichiometry of individual telomerase components
within the telomerase complex [19,23]. Mice heterozygous
for mTert may thus provide a useful genetic model system
in which to test whether deficiencies in other telomerase-
associated proteins exacerbate a partial loss of mTERT
function. Human telomerase activity can be virtually abol-
ished in tumor cell lines by the overexpression of catalyti-
cally inactive hTERT, leading to telomere shortening and
cell death [24–26]. The haploinsufficiency of mTert in ES
cells raises the intriguing possibility that TERT may also
be limiting in immortalized human cells, and that even
a modest reduction of endogenous telomerase activity in
some human tumor cell types may be sufficient to induce
telomere shortening and cell death.
Supplementary material
Supplementary material including additional methodological detail, telom-
erase activity and three figures showing the targeting strategy and TRF
analysis of ES cells is available at http://current-biology.com/supmat/
supmatin.htm.
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Table 1
Chromosomal abnormalities in mTert–/– ES cells or mice.
Aneuploidy End-to-end fusions
Metaphases analyzed (%) (fusions per metaphase)
Splenocytes*
Wild type 25 4 (16%) 0
G1 mTert–/– 25 2 (8%) 0
G2 mTert–/– 20 3 (15%) 0
ES cells
Wild type P1 25 2 (8%) 0
Wild type P30 25 3 (12%) 0
Wild type P50 25 9 (36%) 0
mTert+/– P1 23 2 (9%) 0
mTert+/– P30 24 5 (24%) 0
mTert+/– P50 21 9 (43%) 0
mTert–/– P1 25 3 (12%) 0
mTert–/– P30 24 10 (41%) 0.04
mTert–/– P50 50 29 (58%) 0.58 
*Splenocytes were selected using anti-CD3 antibody and interleukin-2.
